login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ELEDON PHARMACEUTICALS INC (ELDN) Stock News
USA
-
Nasdaq
- NASDAQ:ELDN -
US28617K1016
-
Common Stock
1.64
USD
0 (0%)
Last: 12/15/2025, 8:25:36 PM
1.65
USD
+0.01 (+0.61%)
After Hours:
12/15/2025, 8:25:36 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ELDN Latest News, Press Relases and Analysis
All
Press Releases
15 days ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
15 days ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
a month ago - By: Benzinga
- Mentions:
ABP
CHEK
GTBP
DMAC
...
12 Health Care Stocks Moving In Friday's After-Market Session
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
a month ago - By: Benzinga
- Mentions:
IRIX
STXS
SI
LUCY
...
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
a month ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
2 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting
2 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting
3 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
3 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
4 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
4 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
4 months ago - By: The Motley Fool
Eledon Posts Narrower Loss in Q2
4 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
4 months ago - By: Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
Please enable JavaScript to continue using this application.